 Home > Active Ingredient News > Antitumor Therapy > ASCO 2021: Summary Overview and Outlook 21 Overview of the latest breast cancer research (HER2-positive breast cancer column)

ASCO 2021: Summary Overview and Outlook 21 Overview of the latest breast cancer research (HER2-positive breast cancer column)

 Last Update: 2021-06-08
 Source: Internet
 Author: User

Tags

soil analysis kit

3 page

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

The annual meeting of the American Society of Clinical Oncology (ASCO) will be held from June 4 to 8, 2021.

Breast topic summary: breast cancer topics Summary:Breast Cancer

ASCO 2021: Summary Overview and Outlook 21 | Overview of the latest breast cancer research (HER2-positive breast cancer column)

ASCO 2021: Summary Overview and Outlook 19 | Overview of the Latest Breast Cancer Research (Triple Negative Breast Cancer column)

ASCO 2021: Summary Overview and Outlook 15 | Overview of Latest Breast Cancer Research (ER Positive Breast Cancer Column)

ASCO 2021: Summary Overview and Outlook 11 | Overview of Latest Breast Cancer Research (Invasive Breast Cancer Column)

ASCO 2021: Summary Overview and Outlook 10 | Overview of Latest Breast Cancer Research (Triple Negative Breast Cancer Column)

ASCO 2021: Summary Overview and Outlook 8 | Overview of the Latest Research on Breast Cancer (Male Breast Cancer Column)

The engineered toxin body (ETB) consists of a genetic fusion of a proprietary engineering form of Shiga-like toxin A subunit and an antibody-like binding domain.

For details, see: A phase I open-label study to investigate safety and tolerability, efficacy, pharmacokinetics, pharmacodynamics, and immunogenicity of MT-5111 in patients with HER2-positive tumors.

For details, see: For details, see: A phase I open-label study to investigate safety and tolerability, efficacy, pharmacokinetics, pharmacodynamics, and immunogenicity of MT-5111 in patients with HER2-positive tumors.

PREDICT+ is a widely used free online tool, based on traditional clinicopathological characteristics, including HER2, developed to predict the individual mortality of EBC patients and assist clinical decision-making for treatment.

The analysis included 2,794 points.

Among the HER2+ EBC patients who participated in the ALTTO trial, the PREDICT+ score severely underestimated OS.

For details, see: The prognostic performance of PREDICT+ in patients (pts) with HER2-positive (HER2+) early-stage breast cancer (EBC)

For details, see: For details, see: The prognostic performance of PREDICT+ in patients (pts) with HER2-positive (HER2+) early-stage breast cancer (EBC)

Pilotinib is a new type of irreversible tyrosine kinase inhibitor (TKI) that can significantly improve the progression-free survival (PFS) of patients with HER2+ metastatic breast cancer (MBC).

This is an open-label, multi-center, randomized controlled trial.

51 cases completed 6 cycles of neoadjuvant treatment and successfully operated (21 cases in the treatment group and 30 cases in the control group).

In this study, TCBH+Py neoadjuvant therapy significantly increased the tpCR rate of HER2+ breast cancer patients, which was about twice that of TCBH, and the safety was controllable.

For details, see: Pyrotinib as neoadjuvant therapy for HER2+ breast cancer: A multicenter, randomized, controlled, phase II trial

For details, see: Pyrotinib as neoadjuvant therapy for HER2+ breast cancer: A multicenter, randomized, controlled, phase II trial For details, see: For details, see:Pyrotinib as neoadjuvant therapy for HER2+ breast cancer: A multicenter, randomized, controlled, phase II trial

4.
A retrospective study on the characteristics and survival of patients with breast cancer brain metastases classified by subtype using the NCI SEER registration

Breast cancer brain metastasis (BCBM) new occurrence is associated with the worst prognosis of all types of breast cancer (BC) metastasis.
Analysis of factors related to BCBM stratified by BC subtype may lead to early identification of metastases.

1,268 BCBM patients at the time of BC diagnosis and known clinical subtypes (580 HR+/HER2-, 225 HR+/HER2+, 176 HR-/HER2+ and 287 HR-/HER2-) were used from 2010 to 20 years old in 2017 NCI's Surveillance, Epidemiology, and End Results (SEER) Program 18 registration is determined.
Chi-square and Kaplan-Meier methods were used to analyze baseline characteristics and survival rates.

Compared with all BC patients, HR-/HER2+ BC patients are the most likely to develop BCBM (prevalence 13.
9% vs.
4.
7%; p<0.
001).
Further analysis showed that compared with HER2- patients, the odds ratio of BCBM in HER2+ patients was 2.
52 (95% CI: 2.
24-2.
84).
Interestingly, among HR-/HER2+ BC patients aged 20-39, the brain metastasis rate in the BCBM group was higher than all HR-/HER2+ breast cancer cases (28% vs.
7.
6%; p<0.
001).
The same trend was also seen in the HR-/HER2+ African-American population.
Compared with all BC cases with the same subtype, the brain metastasis rate of people in the BCBM group was higher (14.
3% vs.
5.
9%; p< 0.
001).
After exploring insurance demographics, compared with all HR-/HER2+ BC cases, the brain metastasis rate of uninsured HR-/HER2+ BCBM patients was much higher (14.
8% vs.
6.
4%; p=0.
001).
When examining TNM status, it was found that there was a significant association between brain metastasis and increased tumor and lymph node status.
Compared with all BC cases with the same subtype, patients with T4 or N3 status with HR-/HER2+ BCBM showed a higher metastasis rate (p<0.
001).
Analysis of survival results showed that the median overall survival of HR-/HER2+ BCBM patients was 12 months.
The results shown in the table below show that HR-/HER2- BCBM patients have the lowest 5-year survival rate, while HR+/HER2+ BCBM patients have the highest 5-year survival rate.
Note that there is a significant association between brain metastasis and increased tumor and lymph node status.
Compared with all BC cases with the same subtype, patients with T4 or N3 status of HR-/HER2+ BCBM showed a higher metastasis rate (p<0.
001).
Analysis of survival results showed that the median overall survival of HR-/HER2+ BCBM patients was 12 months.
The results shown in the table below show that HR-/HER2- BCBM patients have the lowest 5-year survival rate, while HR+/HER2+ BCBM patients have the highest 5-year survival rate.
Note that there is a significant association between brain metastasis and increased tumor and lymph node status.
Compared with all BC cases with the same subtype, patients with T4 or N3 status with HR-/HER2+ BCBM showed a higher metastasis rate (p<0.
001).
Analysis of survival results showed that the median overall survival of HR-/HER2+ BCBM patients was 12 months.
The results shown in the table below show that HR-/HER2- BCBM patients have the lowest 5-year survival rate, while HR+/HER2+ BCBM patients have the highest 5-year survival rate.

This SEER database study provides an in-depth understanding of the demographics, clinical variables, and results of the clinical subtypes of BC (especially HR-/HER2+) in the United States from 2010 to 2017.
HR-/HER2+ breast cancer patients in the above-mentioned high-risk population should be made aware of the increased brain metastasis rate compared with the general BC population, because early detection of brain metastases in the HR-/HER2+ cohort can improve the survival rate of patients.

For details, see: A retrospective study of characteristics and survival in patients with breast cancer brain metastases classified by subtype using NCI SEER registry

For details see: For details see: For details see: Fordetails see: Fordetails see: A retrospective study of characteristics and survival in patients with breast cancer brain metastases classified by subtype using NCI SEER registry A retrospective study of characteristics and survival in patients with breast cancer brain metastases classified by subtype using NCI SEER registry A retrospective study of characteristics and survival in patients with breast cancer brain metastases classified by subtype using NCI SEER registryA retrospective study of characteristics and survival in patients with breast cancer brain metastases classified by subtype using NCI SEER registryA retrospective study of characteristics and survival in patients with breast cancer brain metastases classified by subtype using NCI SEER registry

This is a column that is being continuously updated, please pay attention to save this column~

This is a column that is being continuously updated, please pay attention to save and bookmark this column~ This is a column that is being continuously updated, please pay attention to save and bookmark this column~

For more information, follow the ASCO special page of Metz Medicine: https://meeting.
medsci.
cn/ASCO2020

https://meeting.
medsci.
cn/ASCO2020

Reference source: https://meetinglibrary.
asco.
org/results?meetingView=2021%20ASCO%20Annual%20Meeting

https://meetinglibrary.
asco.
org/results?meetingView=2021%20ASCO%20Annual%20Meeting

Leave a message here

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.